Confluence Pharmaceuticals

Developing drugs to treat Fragile-X and Austism Spectrum Disorders

placeIndianapolis, Indiana, United States calendar_todayFounded 2010 groups4 employees language confluencepharma.com

Innovation

3 patent families (2 granted) — focus: Human necessities; filing pace slowing. Cited 150 times.

YearFilings
20161
20172
20183
20193
20203
20213
20222
20231
20242

Investor mix

4 investors on record; lead investors include Indiana University, Elevate Ventures, IU Ventures.

Investor typeCountShare
Venture capital250%
Accelerator & incubator125%
Other / undisclosed125%
Coming soon